Corona Remedies IPO

The Corona Remedies IPO looks like a play for quick listing gains rather than a solid long-term investment opportunity. Primarily focused on women's health and chronic medicines domestically, the company's existing manufacturing is already nearing full capacity. Importantly, this IPO doesn't meaningfully fund new production facilities. With most of the ₹500 crore issue being an Offer for Sale, proceeds largely go to selling shareholders, leaving little for the company's growth-focused capital expenditure – a clear negative for future expansion. While revenue and profit have grown, it's primarily driven by margin improvements and price hikes, not significant volume expansion from new internal capacity. This suggests brand strength over production capability. At roughly 40x PE and 11x PB, the valuation appears rich, especially on a price-to-book basis compared to many domestic peers, even if its India-centric focus offers some appeal. My Opinion: Ultimately, Corona Remedies boasts a strong chronic portfolio and brand, but the lack of capacity expansion and high valuations are concerns. Expect potential 20-30% listing gains, making it a viable short-term trade. For long-term investors seeking compounding growth, however, better opportunities exist.